Somagenetix

Series-A
somagenetix.com Biotech & Healthcare
Total Funding Undisclosed
Latest Round Undisclosed Series-A
Last Announced Oct 9, 2024
Investors Undisclosed
Decision Makers 5 Verified

About Somagenetix

Ex-vivo gene therapy for phagocyte disorders. Somagenetix develops lentiviral HSC programs, starting with CGD—advancing safe, durable, one-time treatments.

Sectors & Market Categories

Company Details

Intelligence Dossier

Corporate & Operational Profile

Primary Industry Biotech & Healthcare
Funding Stage Series-A
Global Headquarters Undisclosed
Tracked Since Oct 1, 2026

Web & Domain Identity

Official Website somagenetix.com
Domain Registered Date Undisclosed

Social & Network Presence

X / Twitter Profile Not linked
LinkedIn Corporate Not linked

Company Milestones & Timeline

1 Events
  1. Capital Raise

    Series-A announced

    fundraisingfox.com

Investors & Backers

Investor firms and individual backers were not publicly disclosed in available round filings for Somagenetix.

Funding History

1 Round
Series-A · Oct 9, 2024

Founders & Leadership

1

Janine Reichenbach

Founder & Member of the Board of Directors

Work email & phone locked Unlock →

Press Coverage & Sources

Recently Funded Biotech & Healthcare Startups

View all

Search the startup feeds free with 50 starter credits.

START FREE WITH 50 CREDITS
Recently funded startups
New SaaS launches
Never pay twice for contacts